文献速递传染病防控与疫情报告免疫规划

重组BmVDAC对微小扇头蜱的疫苗效力:在感染和未感染双芽巴贝虫的牛体上的评估

Vaccine efficacy of recombinant BmVDAC on Rhipicephalus microplus fed on Babesia bigemina-infected and uninfected cattle.
PubMed 文献 · Vaccine · 2020-01-09

本研究评估重组微小扇头蜱线粒体电压依赖性阴离子通道蛋白(rBmVDAC)作为抗蜱疫苗的效力及其阻断双芽巴贝虫感染蜱的能力。rBmVDAC免疫原性良好,抗体可特异性识别蜱中肠天然蛋白;在未感染双芽巴贝虫的免疫牛中,对微小扇头蜱侵染的效力为82%,而在感染双芽巴贝虫的免疫牛中效力为34%,且主要效应为蜱卵孵化率降低34%,但蜱体内双芽巴贝虫寄生虫水平未见降低。

要点

  • rBmVDAC免疫牛后,未感染双芽巴贝虫组对蜱侵染的效力为82%,感染组为34%。
  • 感染组蜱卵孵化率较对照组降低34%,但蜱体内双芽巴贝虫水平未见降低。
  • rBmVDAC具有免疫原性,抗体可识别微小扇头蜱中肠天然蛋白。

核心结论

  • rBmVDAC在未感染双芽巴贝虫的牛中抗蜱效力为82%,在感染牛中为34%,主要效应为降低蜱卵孵化率,但未降低蜱体内双芽巴贝虫水平;作者认为rBmVDAC蛋白可作为候选疫苗进行测试以控制蜱侵染。

研究设计与样本

  • 研究评估重组BmVDAC作为抗蜱疫苗的免疫原性及阻断双芽巴贝虫感染蜱的能力,比较接种rBmVDAC的牛与对照组在未感染和感染双芽巴贝虫条件下的蜱侵染效力。

主要发现

  • rBmVDAC具有免疫原性,抗体特异性识别微小扇头蜱中肠天然蛋白。
  • 接种rBmVDAC的牛在未感染双芽巴贝虫时对微小扇头蜱侵染的效力为82%,对照组为参照。
  • 接种rBmVDAC并感染双芽巴贝虫的牛对蜱侵染的效力为34%,低于未感染组的82%。
  • 接种rBmVDAC并感染双芽巴贝虫的牛所养蜱的卵孵化率较对照组降低34%。
  • 接种rBmVDAC的牛所养蜱体内双芽巴贝虫寄生虫水平未见降低。

关键数值与推荐

  • 未感染组:rBmVDAC对微小扇头蜱侵染的效力为82%。
  • 感染组:rBmVDAC对微小扇头蜱侵染的效力为34%。
  • 感染组:蜱卵孵化率较对照组降低34%。
  • 感染组:蜱体内双芽巴贝虫寄生虫水平未见降低。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rhipicephalus microplus is the most widely distributed tick worldwide and causes significant economic losses in the livestock industry. It directly affects hosts (especially in large infestations) by feeding on blood and piercing the skin and indirectly affects hosts as a vector of pathogens that cause infectious diseases, such as bovine babesiosis. Current research on the control of ticks is focused on integrated tick control programmes, including vaccination treatment with acaricides and completely blocking pathogen transmission. Our previous studies showed that R. microplus VDAC (BmVDAC) expression is modulated by Babesia bigemina infection. VDAC is a mitochondrial protein with multiple functions in addition to its primary role as a central component of the apoptotic machinery. In this paper, we evaluated BmVDAC as an anti-tick vaccine and its capacity to block the infection of Babesia bigemina in ticks. Our results demonstrate that rBmVDAC is immunogenic and that antibodies specifically recognize the native protein from midguts of R. microplus. Immunization with rBmVDAC afforded an 82% efficacy against R. microplus infestation in the group of vaccinated cattle compared with the control group. In contrast, rBmVDAC showed a lower efficacy of 34% against tick infestation in cattle vaccinated with rBmVDAC, infested with R. microplus and infected with B. bigemina. The main effect on ticks fed in vaccinated and infected cattle was a 34% reduction in egg fertility (DF) compared to ticks fed on the control group. There was no reduction in the B. bigemina parasite levels of ticks fed on rBmVDAC-vaccinated cattle. These results suggest that the rBmVDAC protein could be tested as a vaccine for the control of tick infestation.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ortega-Sánchez R, Camacho-Nuez M, Castañeda-Ortiz EJ, et al. Vaccine efficacy of recombinant BmVDAC on Rhipicephalus microplus fed on Babesia bigemina-infected and uninfected cattle. Vaccine. 2020. PMID: 31928853. doi:10.1016/j.vaccine.2019.12.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。